JMP Securities Downgrades AN2 Therapeutics to Market Perform
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan downgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Outperform to Market Perform.

February 12, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AN2 Therapeutics downgraded by JMP Securities from Market Outperform to Market Perform.
Downgrades by analysts, especially from outperform to perform, typically signal a less optimistic outlook on the stock's future performance. This can lead to decreased investor confidence and potentially a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100